Oncopeptides AB’s decision to pull the multiple myeloma drug Pepaxto (melphalan flufenamide) off the US market due to an adverse survival trend in the OCEAN confirmatory trial sets a new record for fastest time from US Food and Drug Administration accelerated approval to withdrawal.
The drug’s withdrawal was announced by Oncopeptides just 239 days after its accelerated approval in a heavily pretreated population of...




